Alex1Powell's Categories

Alex1Powell's Authors

Latest Saves

Texas is disputing US election results in 4 swing states: Pennsylvania, Michigan, Wisconsin & Georgia

Under Article III, US Supreme Court settles disputes between 2 or more states

Due to safe harbour, Trump’s remaining legal routes are narrow after

Brief analysis:
The Texas case is about the contested swing states’ executive & judicial branches VS their legislatures, on mail-in ballot rules

On Tuesday before safe harbour, SCOTUS rejected a similar lawsuit brought by Republican Rep. Mike Kelly

But a 3rd & eerily similar case has been with Justice Alito (as circuit judge for PA) & the Supreme Court since before the election. It’s about this very same executive & judiciary VS legislature dispute. That case, PA Republican Party vs Boockvar, may be decided in time, or not


The below is also worth noting:


There is also the issue of ‘safe harbour’ being said to only be “procedural”. This view rests on a reading of the Bush v Gore Supreme Court ruling.
The UK government's climate advisory body is launching its next carbon budget: basically, outlining what the UK can emit between 2033 and 2037. It's a big deal - launch video starting right now.
Watch along:


Will tweet along snippets. Pretty relevant to...............everything, really. #UKCarbonBudget

"Instead of being just a budget, it's a pathway we have to tread to reach net zero in 2050" @lorddeben

Just like quite a few other modelling exercises, CCC use a spectrum between behaviour change and between technological change. #UKCarbonBudget.

Both = best (just like @AEMO_Media's Step Change scenario in their ISP)


'Balanced' is what they use for their recs. "We're doing 60% of the emissions reductions in the first 15 years, and then 40% in the next".

The slinky kitty curve....good to see. No evidence of delaying action to Dec 29 2049, here. #UKCarbonBudget


"By front loading, we're minimising the UK's contribution to cumulative emissions" - really important point. A slow path to net zero - more climate harm than a fast one. #UKCarbonBudget
$ARPO Thread: Raz P2b glaucoma readout Dec 15 to Jan 15, assigning 90% POS, potential 3 to 5x, with (likely) partnership 1H21. Glaucoma dead for Big Pharma unless there’s a brand new MOA or pathway being targeted. Here we have both…a new MOA (Tie2) and a new location (SC)

https://t.co/zsc2eBVI4e Tons of great preclinical work on TIE2 MOA showing clear correlation to SC integrity, adult-onset glaucoma, and disease-modifying effects. See mosaic if interested


What do KOL's think of the new MOA: Special session held at ARVO 2019 to discuss Tie2 for Glaucoma. $ARPO then completed a closely watched P1b with a topical formulation. Now, a P2b trial in 195 pts enrolled within 3 mos, a month ahead of schedule, in the middle of a pandemic.

SOC is PG (-7 mm Hg IOP) +/- adjunct (-1 to -1.5 mm delta). Best efficacy adjunct is Rocklatan (-1.5), but AE profile: hyperemia (60 vs 15%), pruritus (8 vs 2%) site pain (20 vs 7%) vs PG , + other AE’s not seen with PG: 10% conjunctival hemorrhage, 15% verticillata. Almost DOA

But, sells $80 to $100M/yr US (same as $ARPO MC ha!). Every 0.3 mm reduction critical towards delaying vision loss. Rocklatan MOA was projected to make it a $1B drug, until AE profile (& payor delays) killed launch. $ARPO thesis: Raz efficacy >/= Rocklatan, without AE baggage.